Kirby Lee/Image of Sport-USA TODAY Sports

Company Named In Former Trojan Armond Armstead's Lawsuit Files Cross-Complaint Against USC

SportsPharm Pharmaceuticals Inc., one of the companies named in a lawsuit filed by former Trojan Armond Armstead against USC has filed a cross-complaint against the university on Monday, according to ATVN.

Armstead, a former defensive lineman for the Trojans, filed a lawsuit against the school in August 2012 and accuses team doctors of providing him with painkillers that resulted in him having a heart attack and subsequently hurt his chances to get drafted into the NFL. SportsPharm is allegedly responsible for supplying the drug in question to USC.

SportsPharm asks in the cross-complaint that any damages awarded to Armstead be divided among the defendants and that they be compensated by their co-defendants–the USC football team and team physician Dr. James Tibone–for attorney’s fees.

Armstead’s lawsuit alleges that Dr. Tibone and other USC doctors required Armstead to take a pain killer called Toradol without informing him of the potential side effects. According to his lawyers, Dr. Tibone supplied Toradol “without limitation” and “without his informed consent.”

Robert Bale, Armstead’s attorney, says that Toradol is to keep injured players available for action instead of aiding in recovery, while USC attorney Louis Pappas insists that Toradol is a safe drug. Bale also maintains that Armstead was given an ultimatium regarding Toradol: “If you don’t get this shot, you don’t play, and if you don’t play, you don’t get scouted, and if you’re not scouted, you don’t play in the NFL.”

Armstead, 22, suited up for USC from 2008 to 2010. He missed all of 2011 because of his heart condition, and was not chosen in the 2012 NFL Draft. He did however spend last year in the CFL, playing for the Toronto Argonauts. In January 2013, Armstead signed a new deal with the New England Patriots.

Next Trojans Game Full schedule »

Tags: Armond Armstead Football Lawsuit USC Trojans

comments powered by Disqus